Payment overview · 2025
General Payments
$274.81
15 reported records · 8 companies
Healthcare provider profile · identity verified
Logan John Shetlar
Allopathic & Osteopathic Physicians|Family Medicine · LYONS, KS · NPI 1558821843
Verified facts
What the public records show
CMS Open Payments records show Logan John Shetlar received $274.81 in general payments during 2025 across 15 reported records.
Novartis Pharmaceuticals Corporation accounted for 46.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Synthroid by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $128.97 | 46.9% | 6 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $32.87 | 12.0% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $31.15 | 11.3% | 2 | 2025 |
| Organogenesis Inc. | Unresolved — no canonical attribution shown | $30.98 | 11.3% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $17.79 | 6.5% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $16.79 | 6.1% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $14.73 | 5.4% | 1 | 2025 |
| Organon LLC | Unresolved — no canonical attribution shown | $1.53 | 0.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $274.81 | 15 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $128.97 | 6 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $32.87 | 2 | 2025 |
Source payment records
|
|||||
| CYGNUS MATRIX Normalized: cygnus matrix |
Medical Supply | Organogenesis Inc. | $30.98 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $18.39 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $17.79 | 1 | 2025 |
Source payment records
|
|||||
| DEXCOM G7 GSS (161) Normalized: dexcom g7 gss 161 |
Medical Supply | Dexcom, Inc. | $16.79 | 1 | 2025 |
Source payment records
|
|||||
| DEXCOM STELO GLUCOSE BIOSENSOR Normalized: dexcom stelo glucose biosensor |
Not specified | Dexcom, Inc. | $16.79 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $15.78 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $15.78 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $15.37 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $15.37 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $15.37 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $14.73 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $14.73 | 1 | 2025 |
Source payment records
|
|||||
| JADA SYSTEM Normalized: jada system |
Device | Organon LLC | $1.53 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
70 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 266 | 41 |
| Levothyroxine Sodium | Levothyroxine Sodium | 204 | 32 |
| Furosemide | Furosemide | 190 | 33 |
| Losartan Potassium | Losartan Potassium | 187 | 30 |
| Potassium Chloride | Potassium Chloride | 150 | 27 |
| Pantoprazole Sodium | Pantoprazole Sodium | 136 | 29 |
| Lisinopril | Lisinopril | 132 | 25 |
| Sertraline Hcl | Sertraline Hcl | 125 | 18 |
| Gabapentin | Gabapentin | 109 | 17 |
| Amlodipine Besylate | Amlodipine Besylate | 104 | 21 |
| Tamsulosin Hcl | Tamsulosin Hcl | 96 | 23 |
| Omeprazole | Omeprazole | 93 | 14 |
| Metformin Hcl | Metformin Hcl | 88 | 15 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 79 | 24 |
| Montelukast Sodium | Montelukast Sodium | 75 | 13 |
| Eliquis | Apixaban | 70 | 11 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 70 | 16 |
| Prednisone | Prednisone | 66 | 37 |
| Metoprolol Tartrate | Metoprolol Tartrate | 65 | 11 |
| Finasteride | Finasteride | 64 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 61 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 53 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 53 | suppressed |
| Famotidine | Famotidine | 50 | suppressed |
| Meloxicam | Meloxicam | 49 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 49 | suppressed |
| Simvastatin | Simvastatin | 49 | suppressed |
| Lorazepam | Lorazepam | 48 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 45 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 45 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 43 | suppressed |
| Baclofen | Baclofen | 42 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 42 | suppressed |
| Carvedilol | Carvedilol | 41 | suppressed |
| Mirtazapine | Mirtazapine | 41 | suppressed |
| Jardiance | Empagliflozin | 40 | suppressed |
| Memantine Hcl | Memantine Hcl | 40 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 39 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 39 | 31 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 39 | suppressed |
| Azithromycin | Azithromycin | 37 | 28 |
| Clonazepam | Clonazepam | 37 | suppressed |
| Spironolactone | Spironolactone | 37 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 36 | suppressed |
| Ozempic | Semaglutide | 35 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 30 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 29 | suppressed |
| Alprazolam | Alprazolam | 28 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 28 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 27 | suppressed |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 27 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 27 | suppressed |
| Bupropion Xl | Bupropion Hcl | 26 | suppressed |
| Nystatin | Nystatin | 26 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 26 | suppressed |
| Celecoxib | Celecoxib | 25 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 25 | 20 |
| Quetiapine Fumarate | Quetiapine Fumarate | 25 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 24 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 24 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 23 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 22 | suppressed |
| Chlorthalidone | Chlorthalidone | 22 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 22 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 21 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 20 | 17 |
| Pregabalin | Pregabalin | 20 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 20 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 19 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 19 | suppressed |
| Levetiracetam | Levetiracetam | 19 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 19 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 18 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 17 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 17 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 16 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 16 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 15 | 13 |
| Ketoconazole | Ketoconazole | 15 | suppressed |
| Novolog Flexpen | Insulin Aspart | 15 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 15 | suppressed |
| Amoxicillin | Amoxicillin | 14 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | 14 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Sucralfate | Sucralfate | 14 | suppressed |
| Synthroid | Levothyroxine Sodium | 14 | suppressed |
| Xarelto | Rivaroxaban | 14 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 13 | suppressed |
| Fentanyl | Fentanyl | 13 | suppressed |
| Methotrexate | Methotrexate Sodium | 13 | suppressed |
| Naproxen | Naproxen | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 12 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 12 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Latanoprost | Latanoprost | 12 | suppressed |
| Minoxidil | Minoxidil | 12 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 12 | suppressed |
| Allopurinol | Allopurinol | 11 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $274.81 · 15 records | Novartis Pharmaceuticals Corporation | ABRYSVO, COMIRNATY, CYGNUS MATRIX, DEXCOM G7 GSS (161), DEXCOM STELO GLUCOSE BIOSENSOR, ENTRESTO, EVENITY, JADA SYSTEM, LEQVIO, NURTEC ODT, Ozempic, PREVNAR 20, Rybelsus, VRAYLAR, ZAVZPRET | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error